MCRB

Insider Trades

Name	Value	Action	Price	Current Price
Brady KellySee Remarks $44459 shares SellMay 18, 2026 $7.53 --
DesRosier ThomasSee Remarks $59579 shares SellMay 18, 2026 $7.53 --
Henn Matthew R.See Remarks $58077 shares SellMay 18, 2026 $7.53 --
Shaff Eric D.Director $2.0k259 shares SellMay 18, 2026 $7.53 --
DesRosier ThomasSee Remarks $66178 shares SellFeb 15, 2026 $8.47 --
Henn Matthew R.See Remarks $75489 shares SellFeb 15, 2026 $8.47 --

News

globenewswire.comSeres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027globenewswire.comJun 5

globenewswire.comSeres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conferenceglobenewswire.comMay 12

globenewswire.comSeres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updatesglobenewswire.comMay 5

globenewswire.comSeres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Diseaseglobenewswire.comMay 4

Trade MCRB

About Seres Therapeutics, Inc.

Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, has successfully concluded Phase III clinical trials for the management of Clostridioides difficile infection (CDI). The company's pipeline further encompasses SER-155, a synthetically cultured bacterial formulation currently undergoing Phase Ib evaluation. This candidate aims to mitigate the risk of gastrointestinal and bloodstream infections, alongside graft-versus-host disease, in vulnerable patients undergoing allogeneic hematopoietic stem cell or solid organ transplantation. Additionally, Seres Therapeutics is advancing SER-287 and SER-301, both in Phase Ib for ulcerative colitis, as well as SER-401, which targets metastatic melanoma, and SER-262, also directed at Clostridioides difficile infection. Seres maintains strategic alliances through licensing and collaboration agreements with entities such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center. Established in 2010, the company previously operated as Seres Health, Inc. before adopting its current name in May 2015, and it maintains its principal offices in Cambridge, Massachusetts.

CEO: Richard N. Kender
IPO Date: Jun 26, 2015

Market Data

Open: $6.40
High: $6.63
Low: $6.08
Volume: 124.4K
Avg Volume: 57.7K
52W High: $29.98
52W Low: $5.31

Valuation

Market Cap: $64M
Enterprise Value: $115M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $865k
Revenue: $789k
Net Income: $5.7M
Cash: $46M
Debt: $83M

Events

EarningsAug 5

EPS est. -2.3